← Back
NeuroTrials.ai
Neurology Clinical Trial Database

GENERATION HD1

GENERATION HD1: A Phase 3 Trial of Tominersen in Adults with Manifest Huntington's Disease

Year of Publication: 2023

Authors: Peter McColgan, Alpa Thobhani, Lauren Boak, ..., and the GENERATION HD1 Investigators

Journal: New England Journal of Medicine

Citation: N Engl J Med 2023;389:2203-2206

Link: https://www.nejm.org/doi/10.1056/NEJMc2300400


Clinical Question

Does intrathecal administration of tominersen, an antisense oligonucleotide targeting huntingtin mRNA, slow clinical progression in adults with manifest Huntington's disease?

Bottom Line

The GENERATION HD1 trial of intrathecal tominersen in manifest Huntington's disease was stopped early due to unfavorable benefit-risk assessment. The every-8-week dosing regimen showed worse clinical outcomes compared to placebo, while the every-16-week regimen showed no significant clinical benefit. Despite dose-dependent reductions in CSF mutant HTT, increases in ventricular volume without whole-brain atrophy and transient elevation in CSF NfL suggest possible inflammatory or toxic effects.

Major Points

  • Phase 3 randomized, double-blind, placebo-controlled trial with 791 participants with manifest Huntington's disease randomized 1:1:1 to tominersen 120 mg every 8 weeks, every 16 weeks, or placebo
  • Trial was stopped early in March 2021 based on independent data monitoring committee benefit-risk assessment
  • Ad hoc analysis at week 69 showed significantly worse cUHDRS scores in the every-8-week group compared to placebo (-0.54 points, P=0.001) but no significant difference in TFC scores
  • The every-16-week group showed no significant differences from placebo in either cUHDRS or TFC outcomes
  • Tominersen achieved dose-dependent reduction in CSF mutant HTT levels (approximately 40% reduction in every-8-week group, 20% in every-16-week group)
  • Unexpected increases in ventricular volume occurred in both tominersen groups without corresponding whole-brain volume loss
  • Transient increase in CSF neurofilament light (NfL) levels at week 21 in every-8-week group
  • Post hoc analyses suggest younger participants with less disease burden may potentially benefit, leading to GENERATION HD2 phase 2 dose-finding trial

Design

Study Type: Phase 3 randomized, double-blind, placebo-controlled trial

Randomization: 1

Blinding: Double-blind

Follow-up Duration: Planned 101 weeks; trial stopped early with ad hoc analysis at week 69

Countries:

Sample Size: 791

Analysis: Mixed model for repeated measures (MMRM) with ad hoc analysis at week 69 after early trial termination


Inclusion Criteria

  • Adults with manifest Huntington's disease

Arms

FieldTominersen every 8 weeksTominersen every 16 weeksControl
InterventionIntrathecal tominersen 120 mg at randomization, week 4, then every 8 weeksIntrathecal tominersen 120 mg at randomization, week 4, then every 16 weeksIntrathecal placebo matching dosing schedule
DurationPlanned 101 weeks; stopped at week 69Planned 101 weeks; stopped at week 69Planned 101 weeks; stopped at week 69

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Change from baseline in composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 101 (analyzed at week 69 due to early termination). Scores range from -8 to 25, with higher scores indicating improvement.PrimaryBaseline to week 69 change: approximately -1.0 pointsEvery-8-week: -1.54 points; Every-16-week: -1.16 pointsEvery-8-week vs placebo: P=0.001; Every-16-week vs placebo: P=0.84
Change from baseline in Total Functional Capacity (TFC) scale score at week 69SecondaryApproximate -1.1 pointsEvery-8-week: -1.5 points; Every-16-week: -1.14 pointsEvery-8-week vs placebo: P=0.09; Every-16-week vs placebo: P=1.00
Change from baseline in CSF mutant HTT level at week 69SecondaryApproximately 0%Every-8-week: -40%; Every-16-week: -20%
Rate of change in ventricular volume at week 69SecondaryApproximately +10%Every-8-week: +22%; Every-16-week: +14%
Overall adverse eventsAdverseDetailed in supplementary tablesMore adverse events in every-8-week group compared to placebo and every-16-week groups

Subgroup Analysis

Post hoc analyses suggest that younger participants with less disease burden may potentially benefit from tominersen therapy; this hypothesis is being tested in the GENERATION HD2 phase 2 dose-finding trial (NCT05686551)


Criticisms

  • Trial was stopped early, and analysis was ad hoc rather than at the pre-specified primary endpoint (week 101)
  • The mechanism of harm cannot be distinguished between antisense oligonucleotide-related toxic effects versus effects of total HTT lowering
  • Ventricular expansion without whole-brain volume loss is inconsistent with the natural history of Huntington's disease
  • No linear relationship between CSF NfL levels and clinical outcomes was demonstrated
  • Baseline characteristics were not provided in detail in this correspondence letter

Funding

Supported by F. Hoffmann-La Roche

Based on: GENERATION HD1 (New England Journal of Medicine, 2023)

Authors: Peter McColgan, Alpa Thobhani, Lauren Boak, ..., and the GENERATION HD1 Investigators

Citation: N Engl J Med 2023;389:2203-2206

Content summarized and formatted by NeuroTrials.ai.